 Eli Lilly Co. LLY, 1.96 said Wednesday night that its experimental Alzheimers treatment did a better job at clearing amyloid plaque than Eisai and Biogens Aduhelm in a Phase 3 clinical trial. Amyloid plaque is a biomarker associated with Alzheimers. 